CTOs on the Move


 
Founded in 1989, Natus Medical Incorporated is a leading manufacturer of medical devices and software and a service provider for the Newborn Care, Neurology, Sleep, Hearing and Balance markets. Natus products are used in hospitals, clinics and laboratories worldwide. Our mission is to improve outcomes and patient care in target markets through innovative screening, diagnostic and treatment solutions.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.natus.com
  • 6701 Koll Center Parkway Suite 120
    Pleasanton, CA USA 94566
  • Phone: 925.223.6700

Executives

Name Title Contact Details
Courtney Walton
VP, Quality & Regulatory Affairs Profile

Similar Companies

Sultan Healthcare

Sultan Healthcare is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

fast response safety training

fast response safety training is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TDK

TDK is a Mount Prospect, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turenne PharMedCo

Turenne PharMedCo, Inc. is a leading national healthcare service organization offering long term care pharmacy and medical supply solutions to skilled nursing and assisted living facilities, home health agencies, hospice organizations, durable/home medical equipment providers, and other healthcare-related institutions and companies nationwide.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.